Success with pemphigus vulgaris

December 1, 2006

Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.

Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.

Nine of 11 patients with severe disease had remissions lasting up to three years when treated with a combination of Rituxan and IVIG, according to http://MedPageToday.com/.

Two additional patients had complete resolution of lesions after additional infusions of Rituxan alone.